Disease × agent evidence record

Fluticasone Propionate for Asthma: evidence, trials and status

Fluticasone Propionate has both completed registered trials and synthesis-level publications linked to Asthma. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit.

8 registered trials 0 recruiting 17 publications Evidence tier A · Strong Score 80.0
Research Tracker › Pairs › Asthma › Fluticasone Propionate
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

Fluticasone Propionate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. ClinicalTrials.gov lists 8 registered trials linking Fluticasone Propionate to Asthma: 8 have completed. The most advanced is Phase 4 (NCT02388373). The largest enrolment is 815377 participants (NCT01141439). Registration activity spans 2001 to 2014. The literature layer holds 17 publications for this pair: 5 Cochrane reviews, 5 meta-analyses, 2 systematic reviews and 5 clinical trial publications. Publication years run from 2014 to 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.

The RepurpOS disease-intelligence file for Asthma ranks 642 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 26% of childhood-onset asthma in clinical remission by adulthood; <20% adult-onset achieves sustained remission; 65% long-term remission in mild-moderate vs 16% in severe.

Open in Repurposing ExplorerAsthma hubAsthma biomarkers & interventionsChEMBLOpen Targets

Evidence table

Evidence tierA · Strong
Evidence score80.0 (trials 30.0, literature 30.0, tier 15, approved bonus 5.0)
Registered trials8 total: 0 recruiting, 0 active / not yet recruiting, 8 completed, 0 other
Linked publications17 (5 Cochrane reviews, 5 meta-analyses, 5 clinical trial publications, 2 systematic reviews)
Agent typeDrug (Small molecule)
Development stage (any indication)Approved
Mechanism / classNot recorded
Data sourcesOpen Targets, ChEMBL
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

NCT IDTitleStatusPhaseEnrolment
NCT02388373A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down
2014
completedPhase 4225
NCT01520688Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
2012
completedPhase 432
NCT01165138Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
2010
completedPhase 3612
NCT00163371Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)
2005
completedPhase 328
NCT00400855Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate
2005
completedPhase 249
NCT0151607312-Week Study in Adult Subjects With Asthma
2012
completedPhase 2629
NCT01669070A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)
2012
completedPhase 136
NCT01141439Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management
2001
completedNot applicable815,377

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

No mechanism of action is recorded for this pair in the source databases.

OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.

Frequently asked questions

Is Fluticasone Propionate approved for Asthma?

Fluticasone Propionate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is Fluticasone Propionate in clinical trials for Asthma?

ClinicalTrials.gov lists 8 registered trials linking Fluticasone Propionate to Asthma: 8 have completed. The most advanced is Phase 4 (NCT02388373). The largest enrolment is 815377 participants (NCT01141439). Registration activity spans 2001 to 2014.

What does the evidence show for Fluticasone Propionate in Asthma?

Fluticasone Propionate has both completed registered trials and synthesis-level publications linked to Asthma. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.

Cite this page

Open Source Medicine Foundation. Fluticasone Propionate for Asthma: evidence, trials and status. OSMF Research Tracker. Updated 2026-07-05. https://research.opensourcemed.info/pairs/asthma/fluticasone-propionate.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.